These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 34787449)

  • 81. A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults.
    Drazan D; Czajka H; Maguire JD; Pregaldien JL; Maansson R; O'Neill R; Anderson AS; Balmer P; Beeslaar J; Perez JL
    Vaccine; 2022 Jan; 40(2):351-358. PubMed ID: 34961633
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans.
    Toneatto D; Ismaili S; Ypma E; Vienken K; Oster P; Dull P
    Hum Vaccin; 2011 Jun; 7(6):646-53. PubMed ID: 21904120
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The propositive study: Immunogenicity and safety of a four-component recombinant protein-based vaccine against MenB and a quadrivalent conjugate MenACWY vaccine in people living with HIV.
    Isitt C; Bartolf A; Andrews N; Athaide S; Pryce-Williams R; Townsend-Payne K; Borrow R; Ladhani S; Heath PT; Cosgrove CA
    HIV Med; 2023 Sep; 24(9):979-989. PubMed ID: 37088964
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers.
    Tapia MD; Sow SO; Naficy A; Diallo F; Haidara FC; Chaudhari A; Martellet L; Traore A; Townsend-Payne K; Borrow R; Hosken N; Smolenov I; Pisal SS; LaForce FM; Dhere RM; Kapse D; Tang Y; Alderson MR; Kulkarni PS
    N Engl J Med; 2021 Jun; 384(22):2115-2123. PubMed ID: 34077644
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.
    Klein NP; Reisinger KS; Johnston W; Odrljin T; Gill CJ; Bedell L; Dull P
    Pediatr Infect Dis J; 2012 Jan; 31(1):64-71. PubMed ID: 22094635
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study.
    Díez-Domingo J; Simkó R; Icardi G; Chong CP; Zocchetti C; Syrkina O; Bchir S; Bertrand-Gerentes I
    Infect Dis Ther; 2024 Aug; 13(8):1835-1859. PubMed ID: 38955966
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
    Nolan T; Booy R; Marshall HS; Richmond P; Nissen M; Ziegler JB; Baine Y; Traskine M; Jastorff A; Van der Wielen M
    Pediatr Infect Dis J; 2019 Jun; 38(6):643-650. PubMed ID: 31116180
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers.
    Halperin SA; Diaz-Mitoma F; Dull P; Anemona A; Ceddia F
    Eur J Clin Microbiol Infect Dis; 2010 Mar; 29(3):259-67. PubMed ID: 20033465
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.
    Richmond PC; Marshall HS; Nissen MD; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Beeslaar J; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Perez JL;
    Lancet Infect Dis; 2012 Aug; 12(8):597-607. PubMed ID: 22569484
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Comparative Assessment of a Single Dose and a 2-dose Vaccination Series of a Quadrivalent Meningococcal CRM-conjugate Vaccine (MenACWY-CRM) in Children 2-10 Years of Age.
    Johnston W; Essink B; Kirstein J; Forleo-Neto E; Percell S; Han L; Keshavan P; Smolenov I
    Pediatr Infect Dis J; 2016 Jan; 35(1):e19-27. PubMed ID: 26398741
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations.
    Khatami A; Snape MD; Davis E; Layton H; John T; Yu LM; Dull PM; Gill CJ; Odrjlin T; Dobson S; Halperin SA; Langley JM; McNeil SA; Pollard AJ
    Vaccine; 2012 Apr; 30(18):2831-8. PubMed ID: 22394992
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study.
    Zambrano B; Peterson J; Deseda C; Julien K; Spiegel CA; Seyler C; Simon M; Hoki R; Anderson M; Brabec B; Áñez G; Shi J; Pan J; Hagenbach A; Von Barbier D; Varghese K; Jordanov E; Dhingra MS
    Pediatr Res; 2023 Sep; 94(3):1035-1043. PubMed ID: 36899125
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB.
    Bekkat-Berkani R; Fragapane E; Preiss S; Rappuoli R; Sohn WY; Soumahoro L; Vadivelu K
    J Infect; 2022 Nov; 85(5):481-491. PubMed ID: 36087745
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age.
    Baxter R; Baine Y; Ensor K; Bianco V; Friedland LR; Miller JM
    Pediatr Infect Dis J; 2011 Mar; 30(3):e41-8. PubMed ID: 21200360
    [TBL] [Abstract][Full Text] [Related]  

  • 95. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents.
    Jackson LA; Jacobson RM; Reisinger KS; Anemona A; Danzig LE; Dull PM
    Pediatr Infect Dis J; 2009 Feb; 28(2):86-91. PubMed ID: 19116603
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.
    Dull PM; McIntosh ED
    Vaccine; 2012 May; 30 Suppl 2():B18-25. PubMed ID: 22607895
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children.
    Vesikari T; Forsten A; Laudat F; Li P; Van Der Wielen M; Hezareh M; Perez JL; Webber C
    Vaccine; 2020 May; 38(22):3902-3908. PubMed ID: 32284274
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers.
    Tregnaghi M; Lopez P; Stamboulian D; Graña G; Odrljin T; Bedell L; Dull PM
    Int J Infect Dis; 2014 Sep; 26():22-30. PubMed ID: 24980467
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.
    Knuf M; Romain O; Kindler K; Walther U; Tran PM; Pankow-Culot H; Fischbach T; Kieninger-Baum D; Bianco V; Baine Y; Miller J
    Eur J Pediatr; 2013 May; 172(5):601-12. PubMed ID: 23307281
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Potential public health impact of a
    Huang L; Snedecor SJ; Balmer P; Srivastava A
    Postgrad Med; 2022 May; 134(4):341-348. PubMed ID: 33615973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.